Two-sided intensity: both new counterparties arriving and existing ones enlarging in the same recent period
The model's full reasoning — Q4 2023 call → NOWe need answer YES or NO. Need analyze transcript. We need determine if management describes recent period (Q4 2023/full year) business intensified from both directions: new paying counterparties arrived (fresh customers, accounts, partners, programs actually signed/ordered/began transacting in recent period) AND existing counterparties enlarged what they take (existing relationships visibly stepped up orders/scope/volumes/sites/usage/commitments in same recent period by counterparty's choice rather than price increases). Management presents two-sided build as observed current pattern meaningful. We need use only transcript. Let's parse. Company has Tyvaso DPI royalty and manufacturing with United Therapeutics (UT). Also endocrine Afrezza, V-Go. Pipeline 101, 201. Question about "recent period" likely Q4 2023/full year. Management mentions record revenue for Tyvaso on both royalty and collaboration manufacturing, record production on Tyvaso cartridges. Tyvaso DPI royalty revenue grew 132% in Q4, 361% full year due to increase in patient demand and start of commercial sales by UT late Q2 2022. Collaborations and services revenue grew 81% Q4 due to strong Tyvaso DPI production volumes. So existing counterparty UT increased volumes/orders? Yes, record production, revenue growth. That's existing relationship enlarged. New paying counterparties arrived? Need see if management describes fresh customers, accounts, partners, programs that actually signed/ordered/began transacting in recent period. For Tyvaso, UT is existing partner. For Afrezza, new patients? They mention Afrezza net revenue grew 27% due to higher patient demand, paid TRx growth 25%. That is existing product with new patients? "fresh customers" could be patients? But question says "new paying counterparties actually arrived: fresh customers, accounts, partners, or programs that actually signed, ordered, or began transacting in the recent period" Patients are customers? Possibly. But "new paying counterparties" includes customers. Did management describe new patients? They mentioned helped roughly 25,000 patients in 2023, most in history. For endocrine, Afrezza growth driven by volume from higher patient demand. But is that "new customers arrived" or existing patients increased volume? Need distinguish.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| WRBY | Warby Parker Inc. | Q1 2024 | 2024-05-09 | A |
| LINC | Lincoln Educational Services Corporation | Q1 2024 | 2024-05-06 | B+ |
| SNV | Synovus Financial Corp. | Q1 2024 | 2024-04-18 | B |
| PBR | Petróleo Brasileiro S.A. - Petrobras | Q4 2023 | 2024-03-08 | D |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| SBS | Companhia de Saneamento Básico do Estado | Q3 2023 | 2023-11-10 | C+ |
| DASH | DoorDash, Inc. | Q3 2023 | 2023-11-01 | C+ |
| BZUN | Baozun Inc. | Q2 2023 | 2023-08-28 | D |
| VIPS | Vipshop Holdings Limited | Q2 2023 | 2023-08-18 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| PERI | Perion Network Ltd. | Q2 2023 | 2023-08-02 | A |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| SPIR | Spire Global, Inc. | Q1 2023 | 2023-05-10 | B |
| CALX | Calix, Inc. | Q1 2023 | 2023-04-20 | C+ |
| TACT | TransAct Technologies Incorporated | Q4 2022 | 2023-03-08 | A |
| DKS | DICK'S Sporting Goods, Inc. | Q4 2022 | 2023-03-07 | B |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| ADPT | Adaptive Biotechnologies Corporation | Q4 2022 | 2023-02-14 | C+ |
| HIW | Highwoods Properties, Inc. | Q4 2022 | 2023-02-08 | B |
| CNA | CNA Financial Corporation | Q4 2022 | 2023-02-06 | B |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| MEC | Mayville Engineering Company, Inc. | Q3 2022 | 2022-11-05 | B+ |
| SYY | Sysco Corporation | Q1 2023 | 2022-11-01 | C+ |
| KEY | KeyCorp | Q3 2022 | 2022-10-20 | B+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| EVGO | EVgo, Inc. | Q2 2022 | 2022-08-09 | C+ |
| DM | Desktop Metal, Inc. | Q2 2022 | 2022-08-08 | F |
| FLR | Fluor Corporation | Q2 2022 | 2022-08-05 | D |
| IT | Gartner, Inc. | Q2 2022 | 2022-08-02 | A |
| UPWK | Upwork Inc. | Q2 2022 | 2022-07-27 | C+ |
| CME | CME Group Inc. | Q2 2022 | 2022-07-27 | B |
| OGI | OrganiGram Holdings Inc. | Q3 2022 | 2022-07-14 | B+ |
| SE | Sea Limited | Q1 2022 | 2022-05-17 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| OPK | OPKO Health, Inc. | Q1 2022 | 2022-05-09 | D |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| CNXC | Concentrix Corporation | Q1 2022 | 2022-03-30 | B |
| ZENV | Zenvia Inc. | Q4 2021 | 2022-03-17 | C+ |
| SOPH | SOPHiA GENETICS SA | Q4 2021 | 2022-03-15 | C |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| FLUX | Flux Power Holdings, Inc. | Q2 2022 | 2022-02-10 | D |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| OOMA | Ooma, Inc. | Q3 2022 | 2021-12-02 | B+ |
| KTB | Kontoor Brands, Inc. | Q3 2021 | 2021-11-04 | A |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| IRBT | iRobot Corporation | Q3 2021 | 2021-10-28 | D |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| TJX | The TJX Companies, Inc. | Q2 2021 | 2021-08-18 | C |
| UFI | Unifi, Inc. | Q4 2021 | 2021-08-07 | B |
| TENB | Tenable Holdings, Inc. | Q2 2021 | 2021-07-27 | A |
| TCBI | Texas Capital Bancshares, Inc. | Q2 2021 | 2021-07-21 | F |
| CMTL | Comtech Telecommunications Corp. | Q1 2019 | 2018-12-07 | B+ |
| ADSK | Autodesk, Inc. | Q3 2019 | 2018-11-20 | A |
| OGE | OGE Energy Corp. | Q3 2018 | 2018-11-08 | A |
| ROP | Roper Technologies, Inc. | Q2 2018 | 2018-07-26 | A |
| CP | Canadian Pacific Railway Limited | Q2 2018 | 2018-07-19 | B+ |
| MKC | McCormick & Company, Incorporated | Q2 2018 | 2018-06-28 | C+ |
| SATS | EchoStar Corporation | Q1 2018 | 2018-05-10 | C+ |
| BCOV | Brightcove Inc. | Q1 2018 | 2018-04-26 | B+ |
| ALLY | Ally Financial Inc. | Q1 2018 | 2018-04-26 | B+ |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| UPLD | Upland Software, Inc. | Q4 2017 | 2018-03-08 | C+ |
| EPAM | EPAM Systems, Inc. | Q4 2017 | 2018-02-16 | B |
| DLHC | DLH Holdings Corp. | Q1 2018 | 2018-02-06 | C+ |
| UNH | UnitedHealth Group Incorporated | Q4 2017 | 2018-01-16 | A |
| MITK | Mitek Systems, Inc. | Q4 2017 | 2017-11-07 | C+ |
| MKTX | MarketAxess Holdings Inc. | Q3 2017 | 2017-10-25 | C+ |
| SBFG | SB Financial Group, Inc. | Q3 2017 | 2017-10-20 | A |
| GNTX | Gentex Corporation | Q3 2017 | 2017-10-20 | B |
| BCE | BCE Inc. | Q2 2017 | 2017-08-05 | B+ |
| CCOI | Cogent Communications Holdings, Inc. | Q2 2017 | 2017-08-03 | B |
| FLEX | Flex Ltd. | Q1 2018 | 2017-07-28 | F |
| ABM | ABM Industries Incorporated | Q2 2017 | 2017-06-08 | B |
| IONS | Ionis Pharmaceuticals, Inc. | Q1 2017 | 2017-05-09 | C |
| ICFI | ICF International, Inc. | Q1 2017 | 2017-05-06 | B+ |
| ATO | Atmos Energy Corporation | Q1 2017 | 2017-02-08 | A |
| EFSC | Enterprise Financial Services Corp | Q4 2016 | 2017-01-24 | B+ |
| WYY | WidePoint Corporation | Q3 2016 | 2016-11-09 | D |
| BCH | Banco de Chile | Q3 2016 | 2016-10-30 | B+ |
| ULBI | Ultralife Corporation | Q3 2016 | 2016-10-29 | C+ |
| MAT | Mattel, Inc. | Q3 2016 | 2016-10-19 | C |
| VRNS | Varonis Systems, Inc. | Q2 2016 | 2016-08-09 | B+ |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
| WK | Workiva Inc. | Q4 2015 | 2016-03-01 | B |
| HPP | Hudson Pacific Properties, Inc. | Q4 2015 | 2016-02-25 | C |
PFIE · Q1 2023 → YESThe question is about whether management describes intensification from BOTH new paying counterparties AND existing ones enlarging what they take, in the recent period, as observed facts. YES Management describes both new arrivals ("new customers," "new opportunities," "several project opportunities," "notable customers" including specific ones like Equitrans Midstream and Enterprise Products) and existing-customer expansion ("repeat orders," "repeat business," "repeat orders from one of the United States’ largest producers," " 85,000 burner management solutions," "large uptick... on retrofits") as already-completed facts in the recent period. They present the combination—widening the customer base while deepening relationships—as the current observed pattern driving the business forward.
EPAM · Q4 2017 → YESThe question is about whether management describes that in the recent period the company's business intensified from BOTH directions at once: new paying counterparties arrived AND existing ones enlarg...YES Management describes both sides occurring together in the recent period: new engagements with clients (including specific examples like the European multinational and Global Health Services Company that started less than 12 months ago) alongside growth within the top 20 existing accounts (more than 18% year-over-year) and even stronger growth outside those 20 (34%). They frame this as an observed pattern of widening and deepening the business now, with continued diversification and expansion across both new and existing relationships.
UNH · Q4 2017 → YESThe question is about whether management describes that in the recent period the company's business intensified from BOTH directions at once: new paying counterparties arrived AND existing ones enlarg...YES Management describes both new paying counterparties (e.g., new states like West Virginia, hospitals using Rally, healthcare transformation alliance with 10 companies, acquisitions like Banmedica and DaVita) and existing ones enlarging (e.g., serving nearly 1 million more seniors in Medicare, 465,000 more in commercial group, strong growth with existing client base for PBM, doubled Rally IDs, 7% same-store growth for SCA, highest Q4 script growth).